CSC Pharmaceuticals International Competitors and Similar CompaniesClear all
CSC Pharmaceuticals International's competitors and similar companies include Pharmstandard, Turning Point Therapeutics, Agios Pharmaceuticals and NATCO Pharma.
 Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products. |  Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. |  Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. |  NATCO Pharma NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API). | ||
Founding Date | Founding Date 2001 | Founding Date 2003 | Founding Date 2013 | Founding Date 2008 | Founding Date 1981 |
Type | Type Private | Type Subsidiary | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Mumbai, IN HQ | Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Petrovo Dalnee, RU Tomsk, RU Ufa, RU Vol'ginskii, RU | Locations San Diego, US HQ | Locations Cambridge, US HQ | Locations Hyderabad, IN HQ Central Hope Town, IN Chennai, IN Hyderabad, IN Santola, IN Vijayapuri North, IN |
Employees | Employees 6 | Employees 1,77814% increase | Employees 474% decrease | Employees 53611% increase | Employees 4,016 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ₽152.1b (FY, 2024) | Revenue (est.) $30.8m (FY, 2021) | Revenue (est.) $54m (FY, 2025) | Revenue (est.) ₹44.1b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods ₽117b (FY, 2024) | Cost of goods N/A | Cost of goods $6.3m (FY, 2025) | Cost of goods ₹7.5b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ₽35.2b (FY, 2024) | Gross profit N/A | Gross profit $47.7m (FY, 2025) | Gross profit ₹37b (FY, 2025) |
Net income | Net income N/A | Net income ₽22.7b (FY, 2024) | Net income ($236.6m) (FY, 2021) | Net income ($412.8m) (FY, 2025) | Net income ₹18.8b (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Pharmstandard
HQ
Dolgoprudny, RU
Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.
View companyTurning Point Therapeutics
HQ
San Diego, US
Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
View companyAgios Pharmaceuticals
HQ
Cambridge, US
Employees
536↑ 11% increase
Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.
View companyNATCO Pharma
HQ
Hyderabad, IN
Employees
4,016
NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API).
View company